Article Menu
-
Academic Editors
Joanna Katarzyna Strzelczyk
Maciej Misiołek
- Subscribe SciFeed
- Recommended Articles
- Related Info Links
-
More by Authors Links
- on DOAJ
- Patil, S.
- Linge, A.
- Hiepe, H.
- Grosser, M.
- Lohaus, F.
- Gudziol, V.
- Kemper, M.
- Nowak, A.
- Haim, D.
- Tinhofer, I.
- Budach, V.
- Guberina, M.
- Stuschke, M.
- Balermpas, P.
- Grün, J. von der
- Schäfer, H.
- Grosu, A.
- Abdollahi, A.
- Debus, J.
- Ganswindt, U.
- Belka, C.
- Pigorsch, S.
- Combs, S. E.
- Boeke, S.
- Zips, D.
- Jöhrens, K.
- Baretton, G. B.
- Baumann, M.
- Krause, M.
- Löck, S.
- on behalf of the DKTK-ROG, .
- on Google Scholar
- Patil, S.
- Linge, A.
- Hiepe, H.
- Grosser, M.
- Lohaus, F.
- Gudziol, V.
- Kemper, M.
- Nowak, A.
- Haim, D.
- Tinhofer, I.
- Budach, V.
- Guberina, M.
- Stuschke, M.
- Balermpas, P.
- Grün, J. von der
- Schäfer, H.
- Grosu, A.
- Abdollahi, A.
- Debus, J.
- Ganswindt, U.
- Belka, C.
- Pigorsch, S.
- Combs, S. E.
- Boeke, S.
- Zips, D.
- Jöhrens, K.
- Baretton, G. B.
- Baumann, M.
- Krause, M.
- Löck, S.
- on behalf of the DKTK-ROG, .
- on PubMed
- Patil, S.
- Linge, A.
- Hiepe, H.
- Grosser, M.
- Lohaus, F.
- Gudziol, V.
- Kemper, M.
- Nowak, A.
- Haim, D.
- Tinhofer, I.
- Budach, V.
- Guberina, M.
- Stuschke, M.
- Balermpas, P.
- Grün, J. von der
- Schäfer, H.
- Grosu, A.
- Abdollahi, A.
- Debus, J.
- Ganswindt, U.
- Belka, C.
- Pigorsch, S.
- Combs, S. E.
- Boeke, S.
- Zips, D.
- Jöhrens, K.
- Baretton, G. B.
- Baumann, M.
- Krause, M.
- Löck, S.
- on behalf of the DKTK-ROG, .
Need Help?
Order Article Reprints
Journal: Cancers, 2022
Volume: 14
Number: 3031
3031
Article:
A Novel 2-Metagene Signature to Identify High-Risk HNSCC Patients amongst Those Who Are Clinically at Intermediate Risk and Are Treated with PORT
Authors:
by
Shivaprasad Patil, Annett Linge, Hannah Hiepe, Marianne Grosser, Fabian Lohaus, Volker Gudziol, Max Kemper, Alexander Nowak, Dominik Haim, Inge Tinhofer, Volker Budach, Maja Guberina, Martin Stuschke, Panagiotis Balermpas, Jens von der Grün, Henning Schäfer, Anca-Ligia Grosu, Amir Abdollahi, Jürgen Debus, Ute Ganswindt, Claus Belka, Steffi Pigorsch, Stephanie E. Combs, Simon Boeke, Daniel Zips, Korinna Jöhrens, Gustavo B. Baretton, Michael Baumann, Mechthild Krause, Steffen Löck and on behalf of the DKTK-ROGadd
Show full author list
remove
Hide full author list
Link:
https://www.mdpi.com/2072-6694/14/12/3031
MDPI offers high quality article reprints with convenient shipping to destinations worldwide. Each reprint features a 270 gsm bright white cover
and 105 gsm premium white paper, bound with two stitches for durability and printed in full color. The cover design is customized to your article
and designed to be complimentary to the journal.
Cite
Patil, S.; Linge, A.; Hiepe, H.; Grosser, M.; Lohaus, F.; Gudziol, V.; Kemper, M.; Nowak, A.; Haim, D.; Tinhofer, I.; et al. A Novel 2-Metagene Signature to Identify High-Risk HNSCC Patients amongst Those Who Are Clinically at Intermediate Risk and Are Treated with PORT. Cancers 2022, 14, 3031. https://doi.org/10.3390/cancers14123031
Patil S, Linge A, Hiepe H, Grosser M, Lohaus F, Gudziol V, Kemper M, Nowak A, Haim D, Tinhofer I, et al. A Novel 2-Metagene Signature to Identify High-Risk HNSCC Patients amongst Those Who Are Clinically at Intermediate Risk and Are Treated with PORT. Cancers. 2022; 14(12):3031. https://doi.org/10.3390/cancers14123031
Chicago/Turabian StylePatil, Shivaprasad, Annett Linge, Hannah Hiepe, Marianne Grosser, Fabian Lohaus, Volker Gudziol, Max Kemper, Alexander Nowak, Dominik Haim, Inge Tinhofer, and et al. 2022. "A Novel 2-Metagene Signature to Identify High-Risk HNSCC Patients amongst Those Who Are Clinically at Intermediate Risk and Are Treated with PORT" Cancers 14, no. 12: 3031. https://doi.org/10.3390/cancers14123031
APA StylePatil, S., Linge, A., Hiepe, H., Grosser, M., Lohaus, F., Gudziol, V., Kemper, M., Nowak, A., Haim, D., Tinhofer, I., Budach, V., Guberina, M., Stuschke, M., Balermpas, P., Grün, J. v. d., Schäfer, H., Grosu, A.-L., Abdollahi, A., Debus, J., ... on behalf of the DKTK-ROG. (2022). A Novel 2-Metagene Signature to Identify High-Risk HNSCC Patients amongst Those Who Are Clinically at Intermediate Risk and Are Treated with PORT. Cancers, 14(12), 3031. https://doi.org/10.3390/cancers14123031
